期刊文献+

美国风险物质数据库构建经验及启示 被引量:2

The Experience and Enlightenment of the Establishment of American Hazardous Substances Data Bank
下载PDF
导出
摘要 全面的药品信息数据库对于药品评价具有重要意义。美国风险物质数据库在药品信息整合与组织管理方面积累了丰富经验,为该国药品评价工作提供便利。针对我国药品信息数据库及相关方发展现状,建议我国政府借鉴美国风险物质数据库相关经验,主导构建和完善药品信息数据库,同时积极动员社会相关组织参与,从而推进我国药品评价工作。 A comprehensive drug information database is important to drug evaluation. Hazardous Substances Data Bank is rich in the management experience of information and organization, which plays an important part in drug evaluation. On contrast with current condition of China's drug information database and related parts, it suggested the authority of the PRC taking advantage of the experience of Hazardous Substances Data Bank, playing the major role in establishment and improvement of comprehensive drug information database, involving the potential parties. The above effort will give rise to drug evaluation project at home.
出处 《中国药物警戒》 2012年第7期410-413,共4页 Chinese Journal of Pharmacovigilance
基金 "心脑血管疾病新药临床评价技术平台研究(2008ZX09312)"课题项目
关键词 药品信息数据库 安全性评价 药品不良反应 drug information database safety assessment ADR
  • 相关文献

参考文献9

  • 1NLM. Hazardous Substances Data Bank(HSDB) Subset[E,B/OL] .2010- 10-26.http://www.nlm.nih.gov/databases/databases_hsdb.html.
  • 2NLM. Fact Sheet Toxicology and Environmental Health Informa- tion Program [EB/OL].2011-04-06.http://www.nlm.nih.gov/pubs/ factsheets/tehipfs.html.
  • 3SIS.Hazardous Substances Data Bank(HSDB) Homepage[EB/OL]. 2011-02-04.http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen HSDB.
  • 4何玮.HSDB信息组织特征及数据库的使用[J].医学信息(医学与计算机应用),2002,15(12):708-710. 被引量:2
  • 5NLM. HSDB CAS Registry Numbers [EB/OL]. 2011-09-09. http: //toxnet.nlm.nih.gov/help/hsdbcasm.html.
  • 6Philip Wexler. TOXNET: An evolving web resource for toxicology and environmental health information[J]. Toxicology 2001,157: 3-10.
  • 7NLM. Fact Sheet Toxicology and Environmental Health Informa- tion Program[EB/OL].2011-03-08.http://www.nlm.nih.gov/pubs/ factsheets/hsdbfs.html.
  • 8NML.HSDB needs assessment[EB/OL]. 2011-08-26.https://www. fbo.gov/indexs=opportunity&mode=form&id=954f9ca105e5bf75 c75elcd05cSba53e&tab=eore&_cview=1.
  • 9NLM.HSDB: past, present, and future[EB/OL]. 2010-11-26.http:// infocus.nlm.nih.gov/2009/05/hsdb-past-present-and-future.html.

共引文献1

同被引文献34

  • 1杨勇.对风险管理若干原则的探讨[J].安全,2011,32(7):35-36. 被引量:2
  • 2王靓.Web3.0时代互联网营销模式探讨[J].沿海企业与科技,2007(11):107-108. 被引量:11
  • 3AIRMIC,ALARM,IRM.A Risk Management Standard[EB/OL].[2014-04-09].http://www.theirm.org/knowledge-and-resources/risk-management-standards/irms-risk-management-standard/.
  • 4ISO.ISO 31000:2009,Risk management-Principles and guide- lines on implementation [S/OL].(2009-11-15)[2013-12-20].buos://www.iso.ore/obo/ui/#iso:std:iso:31000:ed-l:vl:en,.
  • 5EMEA/CHMP,Guideline on risk management systems for medic- inal products for human use[EB/OL].(2005-11-20)[2013-12-20].http:/Idrug.fda.moph.go.th/zone_admin/files/EPO_S_3_22chmp_ riskmanage_medprd9626805 2005.pdf.
  • 6ICH.Guidance for Industry:E2E Pharmacovigilance Planning [EB/OL].(2005-04-01)[2013-12-20]Jattp://www.fdgov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/ucm073107.pdf.
  • 7FDA.Guidance for Industry:Premarketing Risk Assessment[EB/OL].(2005-03-05)[ 2013-12-20 ].http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126958.pdf.
  • 8Suntharalingam G,Perry M R,Ward S,et al.Cytokine storm in a phase 1 trial of the anti-CD28monoclonalantibodyTGN1412 [J].N.Engl.J.Med.,2006,355(10):1018-1028.
  • 9EMEA.Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products[EB/OL].(2007-07-19)[2014-04-08].http s://firstclinical.condregdocs/doc/?db=INT_EMEA_First.
  • 10FDA,Guidance for Industry:Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers[EB/OL].(2005-07-05)[2013-12-20].http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部